PH12014502282A1 - Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent - Google Patents
Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agentInfo
- Publication number
- PH12014502282A1 PH12014502282A1 PH12014502282A PH12014502282A PH12014502282A1 PH 12014502282 A1 PH12014502282 A1 PH 12014502282A1 PH 12014502282 A PH12014502282 A PH 12014502282A PH 12014502282 A PH12014502282 A PH 12014502282A PH 12014502282 A1 PH12014502282 A1 PH 12014502282A1
- Authority
- PH
- Philippines
- Prior art keywords
- halofenate
- inflammatory agent
- agent
- gout
- patients
- Prior art date
Links
- 229940121363 anti-inflammatory agent Drugs 0.000 title abstract 3
- 239000002260 anti-inflammatory agent Substances 0.000 title abstract 3
- 239000002253 acid Substances 0.000 title abstract 2
- 229950000958 halofenate Drugs 0.000 title abstract 2
- BJBCSGQLZQGGIQ-UHFFFAOYSA-N 2-acetamidoethyl 2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetate Chemical compound C=1C=C(Cl)C=CC=1C(C(=O)OCCNC(=O)C)OC1=CC=CC(C(F)(F)F)=C1 BJBCSGQLZQGGIQ-UHFFFAOYSA-N 0.000 title 1
- 201000005569 Gout Diseases 0.000 title 1
- 201000001431 Hyperuricemia Diseases 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- 229940116269 uric acid Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624186P | 2012-04-13 | 2012-04-13 | |
| PCT/US2013/036474 WO2013155478A1 (en) | 2012-04-13 | 2013-04-12 | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12014502282A1 true PH12014502282A1 (en) | 2014-12-15 |
Family
ID=49325641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12014502282A PH12014502282A1 (en) | 2012-04-13 | 2014-10-10 | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20130274331A1 (enExample) |
| EP (1) | EP2836209A4 (enExample) |
| JP (1) | JP2015512948A (enExample) |
| KR (1) | KR20150002799A (enExample) |
| CN (1) | CN104602686A (enExample) |
| AU (1) | AU2013245675B2 (enExample) |
| CA (1) | CA2870014A1 (enExample) |
| CL (1) | CL2014002728A1 (enExample) |
| EA (1) | EA028495B1 (enExample) |
| HK (1) | HK1204913A1 (enExample) |
| IL (1) | IL235154A0 (enExample) |
| MX (1) | MX2014012376A (enExample) |
| PH (1) | PH12014502282A1 (enExample) |
| SG (1) | SG11201406495UA (enExample) |
| WO (1) | WO2013155478A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2900740T3 (es) | 2012-11-02 | 2022-03-18 | Murray & Poole Entpr Ltd | Tratamiento o prevención de episodios cardiovasculares mediante la administración de colchicina |
| WO2014170755A2 (en) | 2013-04-16 | 2014-10-23 | Murray And Poole Enterprises Limited | Sustained-release formulations of colchicine and methods of using same |
| US9907751B2 (en) | 2016-03-10 | 2018-03-06 | RxOMEG Therapeutics LLC | Composition and method of use of colchicine oral liquid |
| JP2023035118A (ja) * | 2021-08-31 | 2023-03-13 | 国立大学法人広島大学 | 体液サンプリング容器 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| US7576131B2 (en) * | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| CA2716860C (en) * | 2008-03-13 | 2017-08-29 | Wellstat Therapeutics Corporation | Compounds and method for reducing uric acid |
| US20090232745A1 (en) * | 2008-03-14 | 2009-09-17 | Intelliherb, Inc. | Licorice lollipop that inhibits dental caries formation |
| US20100137235A1 (en) * | 2008-10-15 | 2010-06-03 | Mutual Pharmaceutical Company, Inc. | Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics |
| US9060987B2 (en) * | 2011-11-04 | 2015-06-23 | Cymabay Therapeutics, Inc. | Methods for treating gout flares |
| DK2775836T3 (en) * | 2011-11-04 | 2018-12-03 | Cymabay Therapeutics Inc | PROCEDURES FOR TREATING GIG RETURN |
| CA2859689C (en) * | 2011-11-04 | 2018-05-22 | Cymabay Therapeutics, Inc. | Methods for treating gout in patient subpopulations |
| CN109908124A (zh) * | 2011-11-04 | 2019-06-21 | 西玛贝医药公司 | 利用卤芬酯或卤芬酸以及第二尿酸降低剂治疗痛风患者中高尿酸血症的方法 |
-
2013
- 2013-04-12 CN CN201380030570.9A patent/CN104602686A/zh active Pending
- 2013-04-12 SG SG11201406495UA patent/SG11201406495UA/en unknown
- 2013-04-12 MX MX2014012376A patent/MX2014012376A/es unknown
- 2013-04-12 US US13/862,262 patent/US20130274331A1/en not_active Abandoned
- 2013-04-12 EP EP13776027.8A patent/EP2836209A4/en not_active Withdrawn
- 2013-04-12 CA CA2870014A patent/CA2870014A1/en not_active Abandoned
- 2013-04-12 KR KR20147031687A patent/KR20150002799A/ko not_active Withdrawn
- 2013-04-12 HK HK15103663.3A patent/HK1204913A1/xx unknown
- 2013-04-12 WO PCT/US2013/036474 patent/WO2013155478A1/en not_active Ceased
- 2013-04-12 AU AU2013245675A patent/AU2013245675B2/en not_active Ceased
- 2013-04-12 JP JP2015505961A patent/JP2015512948A/ja active Pending
- 2013-04-12 EA EA201491870A patent/EA028495B1/ru not_active IP Right Cessation
-
2014
- 2014-10-10 CL CL2014002728A patent/CL2014002728A1/es unknown
- 2014-10-10 PH PH12014502282A patent/PH12014502282A1/en unknown
- 2014-10-19 IL IL235154A patent/IL235154A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20130274331A1 (en) | 2013-10-17 |
| JP2015512948A (ja) | 2015-04-30 |
| WO2013155478A1 (en) | 2013-10-17 |
| MX2014012376A (es) | 2015-06-05 |
| EP2836209A4 (en) | 2015-11-25 |
| CL2014002728A1 (es) | 2015-06-19 |
| HK1204913A1 (en) | 2015-12-11 |
| SG11201406495UA (en) | 2014-11-27 |
| CN104602686A (zh) | 2015-05-06 |
| EA028495B1 (ru) | 2017-11-30 |
| IL235154A0 (en) | 2014-12-31 |
| KR20150002799A (ko) | 2015-01-07 |
| EA201491870A1 (ru) | 2015-03-31 |
| AU2013245675B2 (en) | 2017-02-09 |
| AU2013245675A1 (en) | 2014-10-30 |
| CA2870014A1 (en) | 2013-10-17 |
| EP2836209A1 (en) | 2015-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA37400A1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| EA201100440A1 (ru) | Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| EA201200793A1 (ru) | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин | |
| BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
| EA201300669A1 (ru) | Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение | |
| MX2011011854A (es) | Dihidropirimidinonas para uso como inhibidores de la bace2. | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
| BR112012025017A2 (pt) | métodos para melhorar a qualidade do sono. | |
| BR112013022332A2 (pt) | métodos para tratamento e/ou prevenção de hiperuricemia ou de um distúrbio metabólico associado com a hiperuricemia, e para melhorar o controle do nível de ácido úrico no sangue, e, composição farmacêutica | |
| MX2021013880A (es) | Polimeros enlazados al proton para administracion oral. | |
| BR112014010729A2 (pt) | métodos para tratamento de ataques de gota | |
| PH12013500411A1 (en) | Treatment of myocardial infarction using tgf - beta antagonists | |
| MX357507B (es) | Metodos para tratar hiperucemia en pacientes con gota utilizando halofenato o acido halofenico y un segundo agente de reduccion de urato. | |
| NZ741318A (en) | Compound for treating or preventing hyperuricemia or gout | |
| HK1210699A1 (en) | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy | |
| RU2014117707A (ru) | Способ лечения пролиферативного заболевания | |
| BR112016029012A2 (pt) | método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina | |
| PH12014502282A1 (en) | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent | |
| MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| CY1124383T1 (el) | Προληψη ή αγωγη παθησης ουρικου οξεος ή ποδαγρας | |
| UA109359C2 (xx) | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном |